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We performed polymerase chain reaction analysis, for Mycobacterium species 16S rRNA, rpoB,  and
IS6110 sequences, on 25 tissue specimens from patients with sarcoidosis and on 25 control tissue speci-
mens consisting of mediastinal or cervical lymph nodes and lung biopsies. Mycobacterium species 16S
rRNA sequences were amplified from 12 (48%) and rpoB sequences from 6 (24%) of the sarcoidosis
specimens. In total, 16S rRNA or rpoB sequences were amplified from 15 sarcoidosis specimens (60%)
but were not detected in any of the control tissues (p=0.00002, chi square). In three specimens, the
sequences resembled Mycobacterium species other than M. tuberculosis. All specimens with sequences
consistent with M. tuberculosis were negative for IS6110. We provide evidence that one of a variety of
Mycobacterium species, especially organisms resembling M. tuberculosis, is found in most patients with
sarcoidosis.
arcoidosis is a multisystem inflammatory disease that
mainly affects lymph nodes and pulmonary tissues and is
characterized by noncaseating granulomata in affected organs
(1). Although the cause of sarcoidosis remains unknown, sev-
eral microorganisms have been proposed as possible etiologic
agents, including bacteria (Borrelia burgdorferi, Proprioni-
bacterium acnes, and  Mycobacterium  species) and viruses
(Human herpesvirus 8, Epstein-Barr virus, Cytomegalovirus,
and Coxsackie B) (2). Metals (beryllium and zirconium), min-
erals (talc and clay), and organic substances (pine tree pollen)
have also been proposed as etiologic agents (2). Efforts to
identify an infectious agent for sarcoidosis using methods such
as histologic staining and routine microbial culture have been
unsuccessful. 
Polymerase chain reaction (PCR) analysis for microbial
DNA serves as an alternative method for identifying infectious
agents. PCR was used to identify the etiologic agents of bacil-
lary angiomatosis (Bartonella henselae) (3) and Whipple’s
disease (Tropheryma whippelii) (4). Because of the substantial
pathologic (5), immunologic (6), epidemiologic (7), and clini-
cal similarities (8,9) between sarcoidosis and infections caused
by Mycobacterium species (particularly tuberculosis), we ana-
lyzed tissue specimens from patients with sarcoidosis for evi-
dence of mycobacterial genes. The results of previous studies
have been inconclusive; some investigators were unable to
demonstrate mycobacterial DNA in sarcoid lesions (10,11),
whereas others have amplified mycobacterial DNA of differ-
ent species (12,13). We examined sarcoidosis and control par-
affin-embedded pulmonary, mediastinal, and cervical tissue




For this study, we selected paraffin-embedded tissue speci-
mens from patients who had had mediastinal or cervical lymph
node resection from 1991 to 2001. Specimens from 44 patients
with sarcoidosis and 57 controls were included. Patients were
included for further study if they met the pathologic and clini-
cal features described and if the specimens, after processing
and DNA extraction, were positive for human β -actin with
PCR analysis. We were unable to retrieve purified protein
derivative status on a systematic basis. Based on these criteria,
25 control and 25 sarcoidosis specimens were further analyzed. 
For inclusion in this study, the following criteria was used
for patients with sarcoidosis:  1) clinical features had to be con-
sistent with sarcoidosis (i.e., acute respiratory illness accompa-
nied by erythema nodosum, hilar adenopathy and arthritis
[Lofgren’s syndrome], or indolent progressive pulmonary dec-
ompensation associated with radiographic findings, such as
hilar adenopathy, reticulonodular infiltrates, or pulmonary
fibrosis); 2) histopathologic features had to be consistent with
sarcoidosis (i.e., specimens from each patient had to have con-
fluent noncaseating granulomas, well circumscribed within the
surrounding tissue with a variable amount of peripheral lym-
phocytic infiltration [5]); 3) known microbial causes for granu-
lomata had to be excluded (i.e., specimens were negative for
microorganisms by hematoxylin and eosin (H&E), fungal, acid
fast bacilli (AFB), and auramine-O stains and on routine bacte-
rial, fungal, and AFB cultures). In each case, histopathologic
specimens were independently reviewed by two pathologists.
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Control lymph node specimens were selected from patients
who had undergone mediastinoscopy or cervical node biopsy
during the same period. In each case, a definitive diagnosis
other than sarcoidosis was made. Control patients were
selected from patients for whom the final diagnoses were fun-
gal infection, lymphoma, and primary or metastatic lung
malignancies (Table 1).         
DNA Extraction
For each patient enrolled in the study, the original paraffin-
embedded tissue block was retrieved from the archives, and
eleven 10-µm sections were cut from each. One section was
stained with H&E for microscopic examination, four sections
were used for extraction of DNA, and the remaining six sec-
tions were stored for future analysis. The specimens were ran-
domly processed for slide preparation, and the microtome
blade was changed between each tissue block. For each sec-
tion from patients with sarcoidosis and for the control speci-
mens with the granulomata, granulomata were microdissected
and extracted by using disposable surgical blades. For those
control specimens without granulomata, all tissue from the
four sections was used for DNA extraction. For all specimens,
DNA was extracted with the Qiagen DNAeasy extraction kit
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions, except that 60 µL of proteinase K was used at a
concentration of 20 mg/mL. Tissue dissection and DNA prepa-
ration were performed in a dedicated clean room, which was
separate from the rooms used for PCR analysis and sequenc-
ing. The extracted DNA was stored at –20°C. Groups of tissue
specimens from patients with sarcoidosis and controls were
processed in parallel during all steps of the procedure, includ-
ing extraction of the DNA, amplification and detection of
mycobacterial DNA, and sequence analysis.
PCR Analysis for 16S rRNA, rpoB, and IS6110
Before PCR amplification, to ensure that the extracted
DNA was of proper quality, we used PCR to verify that DNA
sequences encoding human β -actin could be amplified. The
primers used were 5´ATCATGTTTGAGACCTTCAAC3´ (for-
ward primer) and 5´CAGGAAGGAAGGCTGGAAGAG3´
(reverse primer). The PCR conditions were 35 cycles of ampli-
fication carried out in a DNA Thermal Cycler 480 (Perkin-
Elmer, Wellesley, MA); each cycle consisted of 1 min of dena-
turing at 94°C, 1 min of annealing at 54°C, and 1 min of exten-
sion at 72°C (14). As required, all 50 tissue specimens yielded
human β -actin amplicons and were tested further for the pres-
ence of bacterial DNA. 
For amplification of 16S rRNA sequences, a nested PCR
analysis was performed. The primers FO16S, 5´GATAA
GCCTGGGAAACTGGGTC3´ and RO16S, 5´TTCTCCAC-
CTACCG TCAATCCG3´ were selected to amplify a 344-bp
fragment of the 5´ region (nt 134–477) of mycobacterial 16S
rRNA. Primers FI16S (5´CATGTCTTGTGGTGGAAAG
CG3´) and RI16S (5´TACCGTC AATCCGAGAGAACCC3´)
were selected as nested primers to amplify a 288-bp fragment
(nt 181–468). The PCR conditions for both sets of primers
were as follows: 5 min of denaturing at 94°C, followed by 35
cycles of amplification, consisting of 1 min of denaturing at
94°C, 1 min of annealing at 58°C, and 1 min of extension at
72°C. At the end of the 35 cycles, a final extension cycle of 7
minutes at 72°C was performed. 
For amplification of rpoB sequences, a nested PCR also
was performed. The primers FOrpoB (5´GCAGACGC
TGTTGGAAAACTTG3´) and ROrpoB, (5´TGTTCTGGTCC
ATGAATTGGCTC3´) were selected to amplify a 455-bp frag-
ment of the β  subunit (nt 1,940–2,394) of the M. tuberculosis
RNA polymerase gene. The inner primers were designed as
previously described and used in a nested fashion (nt 1,965–
2,324) to amplify a 360-bp product (15). The PCR conditions
were as described previously for 16S rRNA.
For amplification of IS6110 sequences, PCR analysis
included the use of primers IS1  (5´CCTGCGAGCGTAGGCG
TCGG3´) and IS2 (5´CTCGTCCAGCGCCGCTTCGG3´),
designed to amplify a 123-bp fragment (nt 1,510–1,632) of the
M. tuberculosis IS6110 element (16). The assay used the same
conditions as described previously, with the exception that the
PCR analysis included 30 rather than 25 cycles. 
Negative and positive controls were run in parallel with
each PCR assay. We used genomic DNA extracted from M.
tuberculosis  strain H37rv as positive controls, and DNA
extracted from a paraffin-embedded tissue biopsy from an
AIDS patient with ileocecal tuberculosis as positive controls.
We included the following as negative controls in each PCR
reaction: DNA extracted from nonsarcoid paraffin-embedded
tissue, PCR master mix inoculated with 5 µL of sterile water,
and PCR master mix alone. The DNA extraction was per-
formed in the same manner as described for the sarcoid and
control specimens. 
Determination of DNA Sequence of Amplified Products
The PCR products were purified with the Qiagen
QIAquick PCR purification kit (Qiagen, Valencia, CA) and
sequenced directly on both strands in the Vanderbilt Cancer
Center Core Sequencing Laboratory. In cases in which the sig-
nal was ambiguous, PCR products were cloned into the plas-
mid vector system, pGEM T-Easy (Promega, Madison, WI),
and the nucleotide sequences were then determined. 
Alignments of the 16S rRNA, rpoB, and IS6110 sequences
were performed with the NCBI BLAST program. Statistical
evaluation of significance was determined by using chi-square
analysis or Fisher’s exact test, depending upon anticipated cell
size. Sequences were aligned with ClustalW and subjected to
phylogenetic analysis with HKY85 distance matrices with
Paup 4.0b8 (Sinauer Associates, Sunderland, MA).
Results
Patient and Specimen Characteristics
Of the 25 patients with sarcoidosis, 12% were African
American and 88% Caucasian; 36% were men, and 64% wereRESEARCH
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Table 1. Demographic and pathologic information for sarcoidosis and control tissue specimensa
Patient Age (yrs)/sex Race Source of specimen Pathologic diagnosis Presence of granuloma
1 61/M C Lung Sarcoidosis Yes
2 60/F C Cervical node Sarcoidosis Yes
3 43/F C Mediastinum Sarcoidosis Yes
4 55/F C Mediastinum Sarcoidosis Yes
5 42/M AA Mediastinum Sarcoidosis Yes
6 54/F C Mediastinum Sarcoidosis Yes
7 48/F C Mediastinum Sarcoidosis Yes
8 34/M C Mediastinum Sarcoidosis Yes
9 72/F AA Mediastinum Sarcoidosis Yes
10 42/F C Mediastinum Sarcoidosis Yes
11 42/F C Mediastinum Sarcoidosis Yes
12 68/F C Mediastinum Sarcoidosis Yes
13 37/F C Mediastinum Sarcoidosis Yes
14 45/F C Mediastinum Sarcoidosis Yes
15 46/F C Mediastinum Sarcoidosis Yes
16 38/M C Mediastinum Sarcoidosis Yes
17 33/F C Mediastinum Sarcoidosis Yes
18 26/M C Mediastinum Sarcoidosis Yes
19 55/F AA Mediastinum Sarcoidosis Yes
20 31/M C Mediastinum Sarcoidosis Yes
21 42/M C Lung Sarcoidosis Yes
22 42/F C Mediastinum Sarcoidosis Yes
23 38/M C Mediastinum Sarcoidosis Yes
24 54/F C Mediastinum Sarcoidosis Yes
25 78/M C Mediastinum Sarcoidosis Yes
26 33/M AA Lung Hodgkin’s disease No
27 70/F C Lung Histoplasmosis Yes
28 73/M C Mediastinum Mesothelioma No
29 56/F C Mediastinum Adenocarcinoma No
30 24/M C Lung Cryptococcus Yes
31 75/M C Lung Renal cell cancer No
32 32/M AA Mediastinum Coccidiomycosis Yes
33 41/F C Mediastinum Breast cancer No
34 74/F C Mediastinum Adenocarcinoma No
35 72/F C Mediastinum Large-cell cancer No
36 77/M C Mediastinum Large-cell cancer No
37 72/M AA Mediastinum Large-cell cancer Yes
38 78/F C Mediastinum Adenocarcinoma No
39 72/M C Mediastinum Squamous cell cancer No
40 52/F AA Mediastinum Adenocarcinoma Yes
41 52/F C Mediastinum Breast cancer Yes
42 73/M C Mediastinum Adenocarcinoma YesEmerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1337
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<50 years of age. No specimens were obtained from persons
<18 years of age (Table 1). The control population was 20%
African American and 80% Caucasian; 68% were men. Most
(76%) of the control patients were >50 years of age; the age
and sex of the control patients reflect the patient population
undergoing mediastinoscopy to obtain a tissue diagnosis for
probable malignancy. The control population consisted of
patients with lung cancer (72%), chronic fungal infections
(16%), or lymphoma  (12%) (Table 1). Mediastinal lymph
nodes were the source of specimens from 88% and 84% of the
sarcoid and control patients, respectively. The remaining spec-
imens from each group were obtained from either pulmonary
or cervical lymph node biopsies. Granulomas were present in
all of the sarcoidosis tissue specimens and in 7 of the 25 con-
trol specimens. 
PCR Assay Sensitivities
The sensitivity of the PCR assay for each gene was deter-
mined by PCR analysis of serially diluted genomic DNA from
M. tuberculosis strain H37rv, ranging from 5 ng to 0.05 fg per
µL. One M. tuberculosis genome is estimated to have a mass
of 5 fg (17). For PCR analyses of 16S rRNA, rpoB,  and
IS6110, we consistently achieved a sensitivity of 1–2 gene
copies in each assay. 
16S rRNA PCR of Tissue Specimens
In the PCR for 16S rRNA sequences (Table 2), 12 (48%)
of the 25 sarcoidosis specimens tested positive compared to
none of 25 of the control specimens (p=0.0003, chi square).
Sequence analysis of the PCR products from the sarcoidosis
specimens showed that 8 of the 12 had 100% positional iden-
tity with M. tuberculosis, and 1 possessed 99% positional iden-
tity with M. tuberculosis (patient 15). Sequencing of the 16S
PCR product of patient 15 showed a C→ T substitution at posi-
tion 289 and an A→ G substitution at position 355 (based on
the M. tuberculosis 16S rRNA sequence, GenBank accession
nos. Z83862.1, AJ131120.1, X52917.1, and X58890.1). Three
other sequences were found (in patients 7, 19, and 24) that
most closely resembled other Mycobacterium  species.  The
amplicon sequence from patient 7 possessed an A→ G substi-
tution at position 299 and a C→ A substitution at position 380,
yielding 99% positional identity with M. kansasii. Notably the
sequences of M. kansasii,  M. avium, M. visibilis, and  M.
paratuberculosis  are identical within this region; therefore,
distinguishing between these species is not possible (18). The
amplicon sequence from patient 19 contained a T→ C substitu-
tion at position 434, yielding 99% positional identity with M.
gordonae. The amplicon sequence from patient 24 contained
100% positional identity with M. gordonae and M. bohemicum
(19). The phylogenetic relationships of the mycobacterial
sequences are shown in the Figure and are deposited in Gen-
Bank (accession nos. AF468214, AF468215, and AF468216). 
PCR of Tissue Specimens with Other 
Mycobacterial Primers
With the rpoB PCR, 6 (24%) of the 25 specimens from sar-
coidosis patients yielded a product of 360 bp, which by
sequence analysis in each case was most consistent with M.
tuberculosis. Five sequences amplified from sarcoidosis speci-
mens had 98%–100% positional identity with M. tuberculosis
(patients 1, 3, 8, 14, and 24), whereas one had 95% positional
identity (patient 16) (Table 2). The difference in the rate of
finding M. tuberculosis rpoB sequences (24% in the sarcoido-
sis specimens and none in the control specimens) was also sig-
nificant (p=0.02, Fisher’s exact test). In total, 15 (60%) of the
sarcoidosis specimens had either Mycobacterium 16S rRNA or
rpoB sequences compared with none of the control specimens
(p=0.00002, chi square). Mycobacterial 16S rRNA and rpoB
fragments were amplified from 3 (12%) of the 25 sarcoidosis
specimens (patients 1, 14, and 24). Patients 1 and 14 possessed
sequences that had 100% positional identity with M. tubercu-
losis  16S rRNA and 98%–99% positional identity with M.
tuberculosis rpoB DNA. The products amplified from patient
24 possessed 100% positional identity with M. gordonae 16S
rRNA and 99% positional identity with M. tuberculosis rpoB
DNA. In the region amplified with our 16S primers, a differ-
ence of 14 nt existed between the 16S rRNA of M. tuberculo-
sis and M. gordonae. In the region amplified by using rpoB
primers, a difference of 39 nt existed between rpoB  of  M.
tuberculosis and M. gordonae. 
Table 1, continued. Demographic and pathologic information for sarcoidosis and control tissue specimensa
Patient Age (yrs)/sex Race Source of specimen Pathologic diagnosis Presence of granuloma
43 18/M AA Mediastinum Histoplasmosis No
44 47/M C Mediastinum Hodgkin’s lymphoma No
45 74/M C Mediastinum Large-cell lymphoma No
46 76/M C Mediastinum Adenocarcinoma No
47 75/M C Mediastinum Small-cell cancer No
48 60/M C Mediastinum Adenocarcinoma No
49 73/M C Mediastinum Adenocarcinoma No
50 85/M C Mediastinum Lymphoma No
51 40/M AA Ileum Tuberculosis No
aF, female, M, male; C, Caucasian; AA, African-American.RESEARCH
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None of the sarcoidosis or control patient tissue specimens
yielded IS6110 amplicons (Table 2). In contrast, IS6110 prod-
ucts were consistently found in the positive controls, genomic
DNA from M. tuberculosis H37rv, and DNA extracted from a
paraffin-embedded tissue biopsy of an AIDS patient with ileo-
cecal tuberculosis. Both positive controls were positive in the
16S rRNA, rpoB, and IS6110 PCR assays, and sequence anal-
ysis of the products indicated 100% homology with M. tuber-
culosis. The negative controls were consistently negative. 
Discussion
For this study, we chose patients whose cases were consis-
tent with sarcoidosis or in whom an alternative diagnosis was
made conclusively. We chose this stringent design so that no
borderline tissues were examined. Many cases of disease even-
tually diagnosed as sarcoidosis have atypical findings. If our
present observations are confirmed, such cases will be impor-
tant for future analyses. 
We found evidence of mycobacterial DNA in the granulo-
mas of 24% of sarcoidosis specimens when assessing for
rpoB, 48% in the same population when assessing for 16S
rRNA; in total, 60% were positive for either. We acknowledge
the limitations of studying archival tissue and the possibility of
contamination; however, control tissues did not demonstrate
positive results, making contamination less likely. Earlier stud-
ies have identified the presence of mycobacterial DNA in sar-
coidosis tissue specimens with 30%–50% prevalence
(12,13,20). Instead of a single organism being present, we pro-
vide evidence for a heterogenous population of Mycobacte-
rium species in the sarcoidosis tissue specimens studied.
Although we found evidence of organisms resembling M.
tuberculosis, M. gordonae, and M. kansasii, other studies also
have identified M. avium sequences (12,13).
We also provide DNA sequence evidence for novel myco-
bacteria in patient 15. Although most DNA sequences from
the study patients most closely resemble M. tuberculosis,
Table 2. Analysis of sarcoidosis and control tissue specimens for Mycobacterium 16SrRNA, rpoB, and IS6110a
Sarcoidosis patient 16S rRNA rpoB IS6110 Control patient 16S rRNA rpoB IS6110
1 M. tuberculosis M. tuberculosis -- 26 - - -
2 M. tuberculosis -- 2 7 - - -
3- M. tuberculosis -2 8 - - -
4 M. tuberculosis -- 2 9 - - -
5 M. tuberculosis -- 3 0 - - -
6- - - 3 1 - - -
7 M. kansasii -- 3 2 - - -
8- M. tuberculosis -3 3 - - -
9 M. tuberculosis -- 3 4 - - -
10 - - - 35 - - -
11 M. tuberculosis -- 3 6 - - -
12 - - - 37 - - -
13 - - - 38 - - -
14 M. tuberculosis M. tuberculosis -3 9 - - -
15 NM - - 40 - - -
16 - M. tuberculosis -4 1 - - -
17 - - - 42 - - -
18 M. tuberculosis -- 4 3 - - -
19 M. gordonae -- 4 4 - - -
20 - - - 45 - - -
21 - - - 46 - - -
22 - - - 47 - - -
23 - - - 48 - - -
24 M. gordonae M. tuberculosis -4 9 - - -
25 - - - 50 - - -
51 M. tuberculosis M. tuberculosis M. tuberculosis
H37rv M. tuberculosis M. tuberculosis M. tuberculosis
aNM, novel mycobacterium, resembling M. tuberculosis; H37rv, M. tuberculosis; -, indicates a negative result.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1339
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sequences resembling other mycobacterial species also were
identified (Table 2, Figure). In several previous studies, non-
tuberculosis mycobacteria also have been reported (13). One
novel sequence is most closely related to 16S rDNA from M.
tuberculosis,  a known pulmonary pathogen, rather than to
sequences from other mycobacterial species of lesser viru-
lence. The consistent presence of two single polymorphisms in
the same location in the novel sequence suggests a true poly-
morphism rather than an error introduced by Taq PCR. More-
over, the novel sequence was consistently absent from water,
non-sarcoid paraffin-embedded tissue, and M. tuberculosis
DNA controls. Synonymous substitutions in the M. tuberculo-
sis genome are relatively rare, although genomic variations
have been found in genes associated with antibiotic resistance
(21). The DNA with the polymorphism suggests that a variant
of M. tuberculosis, or a closely related novel mycobacterium,
may be present in the sarcoidosis specimen. 
The presence of M. tuberculosis DNA in 48% of sarcoido-
sis specimens is notable because clear clinical connections
between sarcoidosis and tuberculosis have been made. On
occasion, patients with documented tuberculosis develop sar-
coidosis while on antituberculous treatment or vice versa (22–
24). Mycobacterial DNA in sarcoidosis specimens may
explain the clinical correlation between sarcoidosis and tuber-
culosis. That patients have developed sarcoidosis while on
antituberculous therapy suggests that in those patients M.
tuberculosis was not the etiologic agent of sarcoidosis. That
60% of the specimens we examined showed mycobacterial
DNA agrees with certain previous studies (12,13), but other
studies were negative for mycobacterial DNA (10,11). One
possible explanation for these discordant results is that sarcoi-
dosis represents one group of host responses to infectious
agents of which mycobacteria represent the largest associated
group. Alternatively, Mycobacterium species are present in
many of the lesions but at extremely low levels, on either side
of the threshold of detection. Such a hypothesis of small num-
bers of organisms provoking an intense inflammatory
response, analogous to tuberculoid leprosy (25), could explain
why organisms cannot be detected except by ultrasensitive
methods. Yet another alternative explanation was our observa-
tion of degradation of the mycobacterial signal in the total
DNA extract. We observed that mycobacterial DNA could be
amplified from the positive specimens consistently over a 6–8
month period if the original DNA extract was maintained at –
20oC. After this time period, fresh DNA extractions were nec-
essary to demonstrate the presence of mycobacterial DNA.
The original specimens, in which the mycobacterial DNA
could no longer be amplified, remained positive for human β -
actin by PCR analysis, although the band was weaker, suggest-
ing either that the eukaryotic DNA degraded more slowly than
prokaryotic DNA or that more signal was originally present.
This degradation occurred despite minimizing freeze-thaws of
extracted DNA and maintaining the DNA at –20°C. Our
observation suggests that isolation of mycobacterial DNA
from sarcoidosis specimens is best achieved by performing
PCR analysis on fresh DNA extractions, which may help
explain why other investigators had negative findings. 
Based on these observations, we examined whether M.
tuberculosis DNA was present in the sarcoid granuloma by
testing for the presence of IS6110. PCR analysis for IS6110 is
useful, since IS6110 is typically present in 1–25 copies in
members of the M. tuberculosis complex. M. bovis BCG has
only a single of copy of IS6110, whereas the higher copy num-
bers are typically found in M. tuberculosis isolates (26). We
found no evidence of IS6110 DNA in our sarcoidosis or con-
trol tissue specimens. 
Several possible explanations exist for the presence of
mycobacterial 16S rRNA and rpoB, and the absence of IS6110
in the sarcoid specimens, although these three amplicons were
Figure. Analysis of 16S rRNA sequences from nine Mycobacterium spe-
cies and from 12 patients with sarcoidosis. Phylograms based on nucle-
otide alignments were generated with HKY85 distances matrices using
Paup 4.0b10 (Sinauer Associates, Sunderland MA). Bootstrap values
>50 (based on 500 replicates) are represented at each node, and the
branch length index is represented below the phylogram. For eight
patients, the 16S rRNA sequence was identical to M. tuberculosis, and
for one patient (patient 24) was identical to M. gordonae. For patient 15,
the sequence was closely related to M. tuberculosis; for patient 19, the
sequence was closely related to M. duvalii and M. gordonae; for patient
7, the sequence was less closely related to M. leprae.RESEARCH
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consistently present in our positive controls. First, our assay
for IS6110 may not have been sufficiently sensitive to detect
the very low numbers of M. tuberculosis genomes in the sar-
coidosis tissue specimens. In serial dilution studies, the assay
was sensitive enough to detect one bacterial genome, compara-
ble to results for the nested PCRs for 16S and rpoB. However,
correlating the sensitivity of DNA extracted from bacterial
culture to DNA extracted from formalin-fixed, paraffin-
embedded tissue is not possible. Other laboratories that
reported an assay sensitivity of 1–2 genome copies for IS6110
in sarcoidosis tissue extract were also unable to detect any
IS6110 (11,27–29), which was consistent with our results.
Studies assessing for IS6110 reflect a substantial portion of the
literature that does not support the presence of mycobacterial
DNA in the sarcoidosis tissue specimens (11,27,28,30). 
A second possibility is that M. tuberculosis is present but
the strains do not contain IS6110, since strains that possess one
copy or no copies of IS6110 have been reported (31,32). In the
United States, all of approximately 14,000 strains of M. tuber-
culosis tested have been shown to possess IS6110; some in low-
copy number (33). Therefore, this scenario seems unlikely.
A third explanation is that while the agent we found asso-
ciated with sarcoidosis has a close genetic relationship with M.
tuberculosis, it is not M. tuberculosis. The genes for 16S and
23S are particularly suitable as targets for identifying microor-
ganisms, since they are both well conserved and show varia-
tion indicative of their evolution and interrelationship with
other organisms (34). This genetic variation is the basis for
identifying the species of microorganisms in a particular
genus, as this genetic variation is a constant property. Other
members of the M. tuberculosis-complex (M. tuberculosis
BCG, M. bovis, M. microti, and M. africanum) have 100% 16S
and rpoB homology with M. tuberculosis but belong to differ-
ent species; these strains are usually differentiated from M.
tuberculosis  by biochemical and clinical features. Although
we could not attempt isolation of microorganisms from the
formalin-fixed, paraffin-embedded specimens, future studies
targeted to mycobacteria would be especially useful in con-
firming our observations and in characterizing any association
with sarcoidosis. 
We have found evidence for mycobacterial 16S rRNA and
rpoB sequences in sarcoidosis tissue specimens but not in con-
trol tissue specimens. Upon sequence analysis, the products
were most consistent with M. tuberculosis, but IS6110 could
not be detected from these species. We also provide evidence
of the presence of a heterogeneous mycobacterial population,
including organisms highly related to M. tuberculosis, M. gor-
donae, and M kansasii. This heterogeneous population was
found in individual sarcoidosis samples and, in one case, in the
same sample (patient 24). These findings suggest that while M.
tuberculosis and other Mycobacterium species may not be the
sole microbial agents present in sarcoidosis tissues, they are
commonly present and may play important roles. Further
investigation into their presence and any putative etiologic
agent is warranted.
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